Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Jul 2019 |
| Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab | 19 Jul 2019 |
| Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering | 19 Jul 2019 |
| Major Shareholder Announcement | 19 Jul 2019 |
| Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States | 18 Jul 2019 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019 | 16 Jul 2019 |